Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3B-6527 in Advanced Hepatocellular Carcinoma
NCT02834780Phase 1Completed
- Sponsor
- H3 Biomedicine Inc.
- Start
- Dec 2016
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label, single-arm trial of H3B-6527 in hepatocellular carcinoma (HCC), sponsored by H3 Biomedicine Inc. Primary endpoints: Dose-limiting Toxicities at 21 days, Treatment Emergent Adverse Events and Serious Adverse Events at 36.7 months and 3 more. Started Dec 2016; status: completed.
02
Drugs
H3B-6527
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02834780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834780.